The study subject was FABP4—a newer adipokine which appears to be involved in the pathophysiology not only of GDM but also of adiposity, insulin resistance, T2DM, atherosclerosis, hypertension, coronary artery and cerebrovascular diseases, and metabolic syndrome [18,21,22,23,24,25,26,29,30]. Here, FABP4 is linked to atherosclerosis.